Novan’s Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting

Abstract Accepted for Late-breaking Research Presentation by Dr. Stephen Tyring

Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV, will be presented during a Late-breaking Research forum at the 2017 Annual Meeting of the American Academy of Dermatology, or AAD, in Orlando, Florida.